IWC
GTBP icon

Integrated Wealth Concepts’s GT Biopharma GTBP Stock Holding History

Integrated Wealth Concepts’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6K Buy
40,012
+20,006
+100% +$8.11K ﹤0.01% 4107
2026
Q1 		$8.16K Hold
20,006
– – ﹤0.01% 2272
2025
Q4 		$15.7K Buy
+20,006
New +$14.2K ﹤0.01% 1595

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Integrated Wealth Concepts's GTBP Position: Q2 2026 in Review

Integrated Wealth Concepts increased its GT Biopharma (GTBP) stake by 100% in Q2 2026, buying an estimated $8.11K and bringing the position to 40,012 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4107.

Integrated Wealth Concepts first reported a position in GTBP in Q4 2025 and has held it in 3 quarters since. 59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Integrated Wealth Concepts held 40,012 shares of GT Biopharma worth $19.6K as of Q2 2026.
  • Integrated Wealth Concepts bought 20,006 GT Biopharma shares in Q2 2026, an estimated $8.11K.
  • GT Biopharma made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #4107 holding.
  • Integrated Wealth Concepts first reported a position in GT Biopharma in Q4 2025 and has held it in 3 quarters since.
  • 59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.